Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin

In patients with coronary or peripheral artery disease, the combination of rivaroxaban 2.5 mg twice daily and aspirin 100 mg once daily compared with aspirin 100 mg once daily reduced major adverse cardiovascular events and mortality and increased bleeding. This study sought to explore the effects o...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Journal of the American College of Cardiology Ročník 74; číslo 12; s. 1519
Hlavní autori:	Eikelboom, John W, Bosch, Jacqueline J, Connolly, Stuart J, Shestakovska, Olga, Dagenais, Gilles R, Hart, Robert G, Leong, Darryl P, O'Donnell, Martin, Fox, Keith A A, Bhatt, Deepak L, Cairns, John A, Tasto, Christoph, Berkowitz, Scott D, Cook Bruns, Nancy, Muehlhofer, Eva, Diaz, Rafael, Maggioni, Aldo P, Yusuf, Salim
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States 24.09.2019
Predmet:	Aged Aspirin - administration & dosage Aspirin - adverse effects Coronary Artery Disease - complications Drug Combinations Factor Xa Inhibitors - administration & dosage Factor Xa Inhibitors - adverse effects Female Hemorrhage - chemically induced Humans Male Peripheral Arterial Disease - complications Platelet Aggregation Inhibitors - administration & dosage Platelet Aggregation Inhibitors - adverse effects Rivaroxaban - administration & dosage Rivaroxaban - adverse effects Severity of Illness Index coronary artery disease dual pathway aspirin rivaroxaban bleeding peripheral artery disease
ISSN:	1558-3597, 1558-3597
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!